	US 12,227,769 B2
	Methods and compositions for treating negative-sense single-stranded RNA virus
Jianrong Li, Dublin, OH (US); Mark E. Peeples, Bexley, OH (US); Chuan He, Chicago, IL (US); Stefan Niewiesk, Dublin, OH (US); Mijia Lu, Columbus, OH (US); Miaoge Xue, Columbus, OH (US); Zijie Zhang, Chicago, IL (US); and Boxuan Zhao, Palo Alto, CA (US)
Assigned to The University of Chicago, Chicago, IL (US); Nationwide Children's Hospital, Columbus, OH (US); and The Ohio State University, Columbus, OH (US)
Appl. No. 17/309,038
Filed by The University of Chicago, Chicago, IL (US); Nationwide Children's Hospital, Columbus, OH (US); and The Ohio State University, Columbus, OH (US)
PCT Filed Oct. 18, 2019, PCT No. PCT/US2019/056942 § 371(c)(1), (2) Date Apr. 16, 2021, PCT Pub. No. WO2020/081937, PCT Pub. Date Apr. 23, 2020.
Claims priority of provisional application 62/748,175, filed on Oct. 19, 2018.
Prior Publication US 2022/0033783 A1, Feb. 3, 2022
Int. Cl. A61K 35/76 (2015.01); C12N 7/00 (2006.01)

CPC C12N 7/00 (2013.01) [A61K 35/76 (2013.01); C12N 2760/18522 (2013.01)]

25 Claims

1. An attenuated negative-sense single-stranded RNA virus of the family Pneumoviridae comprising sequence alterations in the viral genome or antigenome corresponding to the G gene encoding one or more N⁶-methyladenosine (m6A) consensus sites, wherein the alterations result in reduction of m6A modifications of viral mRNA, antigenome or genome.